To include your compound in the COVID-19 Resource Center, submit it here.

Alemtuzumab: Phase II

Additional follow-up data from 195 patients in the open-label, U.S. and European Phase II CAMMS223 trial showed that a significantly greater proportion of patients treated with alemtuzumab were free of clinically-active disease, defined as

Read the full 348 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE